Gilead Made Gains In Oncology, Though Virology Remains King

New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021

 
• By Alaric DeArment

Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.

Digital illustration of Cancer cell in colour background
Gilead has made significant strides in developing its oncology business. • Source: Shutterstock

More from Business

More from Scrip